In the TCCSG L04‐16 Study, the EFS and OS rates for BCP-ALL patients was 80% and 92%, respectively, but 50% and 56% respectively for MEF2D-r cases [7]. This evidence concerns the gene MEF2D and acute lymphoblastic leukemia.